ADVFN US – Market Content Editor
-
IonQ shares rise after Vector Atomic acquisition to boost quantum sensing
IonQ Inc. (NYSE:IONQ) saw its stock climb 1.9% in premarket trading Wednesday following the announcement of a definitive agreement to acquire Vector Atomic, a specialist in quantum sensing for positioning, navigation, and timing applications. The all-stock deal is expected to accelerate IonQ’s expansion into the quantum sensing sector while enhancing its full-stack quantum platform. Vector…
-
Workday shares surge 8% premarket as Elliott Management reveals $2B stake
Shares of Workday (NASDAQ:WDAY) jumped over 8% in U.S. premarket trading on Wednesday after activist investor Elliott Management disclosed a stake in the cloud-based HR software company valued at more than $2 billion. Elliott expressed confidence in Workday’s leadership, stating the CEO and CFO “have demonstrated effective management in recent years.” The company, which provides…
-
Eli Lilly stock climbs as oral diabetes therapy beats Novo Nordisk competitor
Eli Lilly and Company (NYSE:LLY) shares rose 1% on Wednesday after the drugmaker reported that its investigational oral GLP-1 treatment, orforglipron, delivered stronger outcomes than Novo Nordisk’s oral semaglutide in a direct Phase 3 comparison. The 52-week ACHIEVE-3 study followed 1,698 adults with type 2 diabetes. Results showed orforglipron produced more significant reductions in blood…
-
Caliber stock jumps after $15.9M preferred equity deal
CaliberCos Inc (NASDAQ:CWD) shares surged 29% in premarket trading Wednesday after the company finalized a $15.9 million securities purchase and launched an At-The-Market (ATM) equity program. The company sold 15,868 Series B Preferred shares at $1,000 each to an institutional investor. These preferred shares are convertible into Caliber common stock at $250 per share, carry…
-
Arrow Electronics shares slide after CEO exit
Arrow Electronics Inc. (NYSE:ARW) saw its stock dip 3.2% in premarket trading Wednesday following an unexpected leadership shake-up. The company announced that board member William (“Bill”) F. Austen has been appointed Interim President and CEO, effective immediately. Austen takes over from Sean Kerins, who has stepped down from his roles as Director, President, and CEO.…
-
Lyft and Waymo to Launch Self-Driving Rides in Nashville in 2026
Lyft Inc. (NASDAQ:LYFT) and Waymo have joined forces to introduce autonomous ride-hailing in Nashville in 2026, the companies announced in a press release. The partnership will leverage Lyft’s Flexdrive subsidiary to manage Waymo’s autonomous fleet, covering vehicle maintenance, infrastructure, and depot operations. Initially, passengers will book rides through the Waymo app, with plans to integrate…
-
Oruka Therapeutics Shares Jump 20% on Strong Phase 1 ORKA-001 Data
Oruka Therapeutics (NASDAQ:ORKA) saw its stock soar 20% on Tuesday following the release of promising interim results from its Phase 1 trial of ORKA-001, a long-acting IL-23p19 antibody for treating plaque psoriasis. The company reported that ORKA-001 demonstrated an approximate half-life of 100 days, more than three times longer than that of risankizumab, a competitor.…
-
Roivant Shares Jump on Positive Phase 3 Data for Dermatomyositis Therapy
Shares of Roivant Sciences (NASDAQ:ROIV) climbed 9% after the company, together with partner Priovant Therapeutics, reported encouraging Phase 3 results for brepocitinib in patients with dermatomyositis, a rare autoimmune disorder. The once-daily oral brepocitinib 30 mg showed statistically significant and clinically meaningful improvements versus placebo across the primary endpoint and all nine key secondary endpoints.…
-
Paramount Shares Drop Following Rithm Capital Acquisition Announcement
Paramount Group, Inc. (NYSE:PGRE) saw its stock fall sharply, tumbling 12% after revealing a definitive agreement to be acquired by Rithm Capital Corp. (NYSE:RITM) in an all-cash deal valued at around $1.6 billion. Under the terms, Rithm will purchase all outstanding Paramount shares at $6.60 per fully diluted share, representing a notable discount from the…
-
Regeneron’s Garetosmab Achieves Over 90% Reduction in Bone Lesions in FOP Study
Regeneron (NASDAQ:REGN) reported positive results from its Phase 3 Optima trial evaluating garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), showing significant reductions in new bone formation. At the 56-week assessment, both dose levels outperformed placebo substantially. Patients receiving 3 mg/kg experienced a 94% decrease in new bone lesions, while those on the 10 mg/kg…